Fierce Pharma Asia—Astellas' first-in-class FDA nod; Otsuka's IgAN win; Samsung Bio's $1.2B contract
Astellas' first-in-class CLDN18.2 drug Vyloy has cleared the FDA. After a positive phase 3 readout, Otsuka is targeting an accelerated approval filing for a kidney disease candidate. Samsung Biologics ...
NEW YORK, June 16, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of UroGen Pharma Ltd. (NASDAQ: URGN). Shareholders who purchased shares of URGN during the class ...
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Circle Pharma, a clinical-stage biopharmaceutical company dedicated to discovering and developing a new generation of macrocycle therapies, today ...
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Circle Pharma, a clinical-stage biopharmaceutical company dedicated to discovering and developing a new generation of macrocycle therapies, today ...
Liminatus Pharma, Inc. is a pre-clinical-stage immuno-oncology company, which engages in developing novel, immune-modulating cancer therapies. The company was founded on November 1, 2020 and is ...
The Case: Robbins LLP reminds stockholders that a class action was filed on behalf of aTyr Pharma, Inc. investors who purchased common stock during the class period because the Company allegedly ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results